Fulcrum Therapeutics, Inc. — Form D

Fulcrum Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2018-09-05. The offering totals $80.0M, of which $80.0M was reported sold. Industry: Biotechnology.

Offering

Filed: 2018-09-05
Form: D
Accession: 0001680581-18-000002
Industry: Biotechnology
Exemptions: 06b
Total offering: $80.0M
Amount sold: $80.0M
Investors: 20
Date of first sale: 2018-08-24
Security types: equity
Revenue range: Decline to Disclose
SEC file number: 021-320649

Issuer

Name: Fulcrum Therapeutics, Inc.
CIK: 0001680581
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2015
Address: 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Phone: 617-651-8851

Officers, directors & promoters (13)

Name	Role	Location
James Tananbaum	Director	South San Francisco, CA
Amit Hasija	Executive Officer	Cambridge, MA
Alan Ezekowitz	Director	WATERTOWN, MA
James Collins	Director	Cambridge, MA
Mark Levin	Director	New York, NY
Robert Gould	Director	Portland, ME
Robert Gould	Executive Officer	Portland, ME
James Geraghty	Director	Cambridge, MA
Diego Cadavid	Executive Officer	Cambridge, MA
Kate Haviland	Director	Cambridge, MA
Katina Dorton	Director	Cambridge, MA
Bryan Stuart	Executive Officer	Cambridge, MA
Owen Wallace	Executive Officer	Cambridge, MA

Other filings by this issuer (4)

Filed	Form	Offering	Sold
2020-06-11	D	$68.5M	$68.5M
2017-07-25	D/A	$55.0M	$29.7M
2017-05-10	D	$5.0M	$5.0M
2016-07-25	D	$55.0M	$17.0M

More